Can Repurposed Drugs Reverse Established Fibrosis? Evidence from Experimental and Clinical Studies

Can repurposed drugs reverse established fibrosis? This narrative mini-review examines experimental and clinical evidence on five drugs: metformin, simvastatin, losartan, pentoxifylline, and colchicine. It asks whether each study shows a lower matrix burden at the end of treatment, a decline from the burden present when treatment began, or a reduction that persists after drug clearance. An evidence table summarises 12 comparisons from 10 primary studies, documenting treatment timing, evidence of fibrosis at baseline, comparators, outcomes, and follow-up. Delayed metformin and simvastatin reduced final lung collagen burden in experimental models, while the clinical studies showed mixed or inconclusive histological results. None of the reviewed comparisons established that a reduction persisted after drug clearance. The review outlines how pretreatment measurements, concurrent controls, and post-treatment follow-up can help determine whether an intervention slows further matrix accumulation or produces durable regression of established fibrosis.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-16
DOI
https://doi.org/10.5281/zenodo.24292316
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Can Repurposed Drugs Reverse Established Fibrosis? Evidence from Experimental and Clinical Studies

Christiano Gondim Moreira
4 links
Zenodo (CERN European Organization for Nuclear Research)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
preprint

Can Repurposed Drugs Reverse Established Fibrosis? Evidence from Experimental and Clinical Studies

Christiano Gondim Moreira
preprint en

Abstract

Can repurposed drugs reverse established fibrosis? This narrative mini-review examines experimental and clinical evidence on five drugs: metformin, simvastatin, losartan, pentoxifylline, and colchicine. It asks whether each study shows a lower matrix burden at the end of treatment, a decline from the burden present when treatment began, or a reduction that persists after drug clearance. An evidence table summarises 12 comparisons from 10 primary studies, documenting treatment timing, evidence of fibrosis at baseline, comparators, outcomes, and follow-up. Delayed metformin and simvastatin reduced final lung collagen burden in experimental models, while the clinical studies showed mixed or inconclusive histological results. None of the reviewed comparisons established that a reduction persisted after drug clearance. The review outlines how pretreatment measurements, concurrent controls, and post-treatment follow-up can help determine whether an intervention slows further matrix accumulation or produces durable regression of established fibrosis.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon